Accès gratuit
Numéro
Ann. Fr. Med. Urgence
Volume 7, Numéro 3, Juin 2017
Page(s) 197 - 200
Section Cas clinique / Case report
DOI https://doi.org/10.1007/s13341-017-0749-x
Publié en ligne 25 mai 2017
  • Kirchhof P, Benussi S, Kotecha D, et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 37:2893–962 [CrossRef] [PubMed] [Google Scholar]
  • Camm AJ, Lip GYH, De Caterina R, et al (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J 33:2719–47 [CrossRef] [PubMed] [Google Scholar]
  • Bancroft T, Lim J, Wang C, et al (2016) Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther 38:545–56 [CrossRef] [PubMed] [Google Scholar]
  • Nielsen PB, Skjøth F, Søgaard M, et al (2017) Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356:j510 [CrossRef] [Google Scholar]
  • Pernod G, Albaladejo P, Godier A, et al (2013) Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d'intérêt en Hémostase Périopératoire (GIHP) - mars 2013. Ann Fr Anesth Reanim 32:691–700 [CrossRef] [PubMed] [Google Scholar]
  • Godier A, Martin AC, Leblanc I, et al (2010) Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations. Thromb Haemost 103:1116–27 [CrossRef] [PubMed] [Google Scholar]
  • Heidbuchel H, Verhamme P, Alings P, et al (2013) European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15:625–51 [CrossRef] [PubMed] [Google Scholar]
  • Albaladejo P, Pernod G, Godier A, et al (2016) Prise en charge des hémorragies et des gestes invasifs urgents chez les patients recevant un anticoagulant oral et direct anti-IIa (dabigatran). Réactualisation des propositions du Groupe d'Intérêt en Hémostase Périopératoire (GIHP) - septembre 2016. http://site.geht.org/UserFiles/file/NACO/nouvelles_propositions_GIHP_urgences_dabigatran_septembre2016.pdf (Dernier accès le 4 mai 2017) [Google Scholar]
  • Zahir H, Brown KS, Vandell AG, et al (2015) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131:82–90 [CrossRef] [PubMed] [Google Scholar]
  • Connolly SJ, Milling TJJr, Eikelboom JW, et al (2016) Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375:1131–41 [CrossRef] [PubMed] [Google Scholar]
  • Ansell JE, Bakhru SH, Laulicht BE, et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371:2141–2 [CrossRef] [PubMed] [Google Scholar]
  • Pollack CVJr, Reilly AP, Eikelboom J, et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–20 [CrossRef] [PubMed] [Google Scholar]
  • Quintard H, Viard D, Drici MD, et al (2017) Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding. Thromb Haemost 117:196–7 [CrossRef] [PubMed] [Google Scholar]
  • Sauter TC, Blum S, Nagler M, et al (2016) Reversal of dabigatran using idarucizumab in a septic patient with impaired kidney function in real-life practice. Case Rep Emerg Med 2016:1393057 [PubMed] [Google Scholar]
  • Hofer S, Philipsenburg C, Weigand MA, Brenner T (2016) Reversal of anticoagulation with dabigatran in an 82-year-old patient with traumatic retroperitoneal arterial bleeding using the new antidote idarucizumab: a case report. A A Case Rep 7:227–31 [CrossRef] [PubMed] [Google Scholar]
  • Held V, Eisele P, Eschenfelder CC, Szabo K (2016) Idarucizumab as antidote to intracerebral hemorrhage under treatment with dabigatran. Case Rep Neurol 8:224–8 [CrossRef] [PubMed] [Google Scholar]
  • Peetermans M, Pollack CJr, Reilly P, et al (2016) Idarucizumab for dabigatran overdose. Clin Toxicol 54:644–6 [CrossRef] [PubMed] [Google Scholar]
  • Shapiro S, Bhatnagar N, Khan A, et al (2016) Idarucizumab for dabigatran overdose in a child. Br J Haematol [in press] [Google Scholar]
  • Schäfer N, Müller A, Wüllner U (2016) Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab - A case report. J Stroke Cerebrovasc Dis 25:e126–7 [CrossRef] [PubMed] [Google Scholar]
  • Berrouschot J, Stoll A, Hogh T, Eschenfelder CC (2016) Intravenous thrombolysis with recombinant tissue-type plasminogen Aactivator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke 47:1936–8 [CrossRef] [PubMed] [Google Scholar]
  • Scappaticci F, Skillings J, Holden S, et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232–9 [CrossRef] [PubMed] [Google Scholar]
  • Zhu X, Tian X, Yu C, et al (2016) Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials. Medicine 95:e4232. [CrossRef] [PubMed] [Google Scholar]
  • Bosscha K, Reijnders K, Hulstaert PF, et al (1997) Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis. J Surg 84:1532–4 [Google Scholar]
  • Gould MK, Garcia DA, Wren SM, et al (2012) Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis. 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 14:e227S–77S [CrossRef] [PubMed] [Google Scholar]
  • Harrison MH, Edwards RJ, Graveney MJ, et al (1981) Blood volume and plasma protein responses to heat acclimatization in humans. J Appl Physiol Respir Environ Exerc Physiol 50:597–604 [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.